转移性乳腺癌的节拍化疗——文献系统综述
Metronomic Chemotherapy for Metastatic Breast Cancer - a Systematic Review of the Literature.
作者信息
Banys-Paluchowski M, Schütz F, Ruckhäberle E, Krawczyk N, Fehm T
机构信息
Department of Gynecology and Obstetrics, Marienkrankenhaus Hamburg, Hamburg.
Department of Gynecology and Obstetrics, Heidelberg University Hospital, University of Heidelberg, Heidelberg.
出版信息
Geburtshilfe Frauenheilkd. 2016 May;76(5):525-534. doi: 10.1055/s-0042-105871.
Abstract
Conventional chemotherapy is generally administered in high doses followed by a treatment-free period to give the body needful time to recover. This "maximum tolerated dose" approach results in high response rates. However, long periods between therapy cycles can lead to development of resistance mechanisms and consequently disease progression. One of the most interesting alternative strategies is metronomic chemotherapy. This concept relies on the continuous administration of chemotherapy at low doses and aims at targeting endothelial cells in the tumor bed as well. Recently, metronomic chemotherapy has been incorporated into the recommendations issued by the German AGO expert panel (www.ago-online.de). A systematic review of PubMed/Medline, ClinicalTrials.gov, the European Clinical Trials Database (EudraCT) and the Cochrane Database was conducted. In the present review, we discuss the current evidence on metronomic chemotherapy in metastatic breast cancer.
摘要
传统化疗通常采用高剂量给药，随后是无治疗期，以便身体有足够时间恢复。这种“最大耐受剂量”方法可带来较高的缓解率。然而，治疗周期之间的长时间间隔会导致耐药机制的形成，进而导致疾病进展。最有趣的替代策略之一是节拍化疗。这一概念依赖于低剂量持续给予化疗，其目标还包括肿瘤床中的内皮细胞。最近，节拍化疗已被纳入德国AGO专家小组发布的建议中（www.ago-online.de）。我们对PubMed/Medline、ClinicalTrials.gov、欧洲临床试验数据库（EudraCT）和考克兰数据库进行了系统综述。在本综述中，我们讨论了转移性乳腺癌节拍化疗的当前证据。
相似文献
1
Metronomic Chemotherapy for Metastatic Breast Cancer - a Systematic Review of the Literature.转移性乳腺癌的节拍化疗——文献系统综述
Geburtshilfe Frauenheilkd. 2016 May;76(5):525-534. doi: 10.1055/s-0042-105871.
2
Metronomic Chemotherapy for Primary Non-Metastatic Breast Cancer - a Systematic Review of the Literature.用于原发性非转移性乳腺癌的节拍化疗——文献系统综述
Geburtshilfe Frauenheilkd. 2017 Feb;77(2):142-148. doi: 10.1055/s-0043-100388.
3
Low-dose metronomic chemotherapy: a systematic literature analysis.低剂量节拍化疗：系统文献分析。
Eur J Cancer. 2013 Nov;49(16):3387-95. doi: 10.1016/j.ejca.2013.06.038. Epub 2013 Jul 20.
4
The potential clinical promise of 'multimodality' metronomic chemotherapy revealed by preclinical studies of metastatic disease.临床前转移疾病研究揭示“多模式”节拍化疗的潜在临床前景。
Cancer Lett. 2017 Aug 1;400:293-304. doi: 10.1016/j.canlet.2017.02.005. Epub 2017 Feb 12.
5
Metronomic chemotherapy: A potent macerator of cancer by inducing angiogenesis suppression and antitumor immune activation.节拍化疗：通过抑制血管生成和激活抗肿瘤免疫来强力破坏肿瘤。
Cancer Lett. 2017 Aug 1;400:243-251. doi: 10.1016/j.canlet.2016.12.018. Epub 2016 Dec 23.
6
A systematic literature analysis of correlative studies in low-dose metronomic chemotherapy trials.低剂量节拍化疗试验相关研究的系统文献分析
Biomark Med. 2014;8(6):893-911. doi: 10.2217/bmm.14.14.
7
Metronomic chemotherapy for cancer treatment: a decade of clinical studies.节拍化疗治疗癌症：十年的临床研究。
Cancer Chemother Pharmacol. 2013 Jul;72(1):13-33. doi: 10.1007/s00280-013-2125-x. Epub 2013 Mar 9.
8
Metronomic chemotherapy in metastatic colorectal cancer.节拍化疗治疗转移性结直肠癌。
Cancer Lett. 2017 Aug 1;400:319-324. doi: 10.1016/j.canlet.2017.02.034. Epub 2017 Mar 6.
9
Metronomic chemotherapy and nanocarrier platforms.节拍化疗和纳米载体平台。
Cancer Lett. 2017 Aug 1;400:232-242. doi: 10.1016/j.canlet.2016.11.007. Epub 2016 Nov 10.
10
Synergistic antitumor effects of combination treatment with metronomic doxorubicin and VEGF-targeting RNAi nanoparticles.表阿霉素节拍化疗联合 VEGF 靶向 RNAi 纳米粒的协同抗肿瘤作用
J Control Release. 2017 Dec 10;267:203-213. doi: 10.1016/j.jconrel.2017.08.015. Epub 2017 Aug 16.
引用本文的文献
1
Case report: An exceptional responder of low-dose continuous 5-FU in a patient with stage IV triple-negative breast cancer with liver and bone marrow failure.病例报告：一名IV期三阴性乳腺癌伴肝和骨髓衰竭患者对低剂量持续5-氟尿嘧啶的特殊反应。
Front Oncol. 2024 Jan 15;13:1305584. doi: 10.3389/fonc.2023.1305584. eCollection 2023.
2
Capecitabine Plus Aromatase Inhibitor as First Line Therapy for Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer.卡培他滨联合芳香化酶抑制剂作为激素受体阳性、HER2 阴性转移性乳腺癌的一线治疗。
Curr Oncol. 2023 Jun 24;30(7):6097-6110. doi: 10.3390/curroncol30070454.
3
Pharmacokinetics of Carboplatin in Combination with Low-Dose Cyclophosphamide in Female Dogs with Mammary Carcinoma.卡铂联合低剂量环磷酰胺在患有乳腺癌的雌性犬体内的药代动力学
Animals (Basel). 2022 Nov 10;12(22):3109. doi: 10.3390/ani12223109.
4
Advancements in Human Breast Cancer Targeted Therapy and Immunotherapy.人类乳腺癌靶向治疗与免疫治疗的进展
J Cancer. 2021 Oct 11;12(23):6949-6963. doi: 10.7150/jca.64205. eCollection 2021.
5
Antibody-drug conjugates, cancer immunotherapy, and metronomic chemotherapy as novel approaches in cancer management.抗体药物偶联物、癌症免疫疗法和节拍化疗作为癌症管理的新方法。
Indian J Pharmacol. 2020 Sep-Oct;52(5):402-413. doi: 10.4103/ijp.IJP_475_18.
6
Metastatic feline mammary cancer: prognostic factors, outcome and comparison of different treatment modalities - a retrospective multicentre study.猫转移性乳腺肿瘤：预后因素、结果和不同治疗方式的比较——一项回顾性多中心研究。
J Feline Med Surg. 2021 Jun;23(6):549-556. doi: 10.1177/1098612X20964416. Epub 2020 Oct 20.
7
Searching for Goldilocks: How Evolution and Ecology Can Help Uncover More Effective Patient-Specific Chemotherapies.寻找金发姑娘：进化和生态学如何帮助发现更有效的个体化化疗。
Cancer Res. 2020 Dec 1;80(23):5147-5154. doi: 10.1158/0008-5472.CAN-19-3981. Epub 2020 Sep 15.
8
A Pilot Study of Extended Adjuvant Therapy with Metronomic Docetaxel for Patients with Operable Triple-Negative Breast Cancer.多西他赛节拍化疗用于可手术三阴性乳腺癌患者的延长辅助治疗的初步研究。
Asian Pac J Cancer Prev. 2020 Mar 1;21(3):749-754. doi: 10.31557/APJCP.2020.21.3.749.
9
Explorative Analysis of Low-Dose Metronomic Chemotherapy with Cyclophosphamide and Methotrexate in a Cohort of Metastatic Breast Cancer Patients.环磷酰胺与甲氨蝶呤低剂量节拍化疗在一组转移性乳腺癌患者中的探索性分析
Breast Care (Basel). 2018 Aug;13(4):272-276. doi: 10.1159/000487629. Epub 2018 May 3.
10
Spatial Heterogeneity and Evolutionary Dynamics Modulate Time to Recurrence in Continuous and Adaptive Cancer Therapies.空间异质性和进化动态调节连续和适应性癌症治疗的复发时间。
Cancer Res. 2018 Apr 15;78(8):2127-2139. doi: 10.1158/0008-5472.CAN-17-2649. Epub 2018 Jan 30.
本文引用的文献
1
SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase III trial.SAKK 24/09：贝伐单抗联合紫杉醇与贝伐单抗联合节拍性环磷酰胺及卡培他滨作为HER2阴性晚期乳腺癌患者一线治疗的安全性和耐受性——一项多中心、随机III期试验
BMC Cancer. 2016 Oct 10;16(1):780. doi: 10.1186/s12885-016-2823-y.
2
Efficacy and safety of capecitabine-based first-line chemotherapy in advanced or metastatic breast cancer: a meta-analysis of randomised controlled trials.卡培他滨一线化疗用于晚期或转移性乳腺癌的疗效和安全性：一项随机对照试验的荟萃分析
Oncotarget. 2015 Nov 17;6(36):39365-72. doi: 10.18632/oncotarget.5460.
3
Prospective study of cyclophosphamide, thiotepa, carboplatin combined with adoptive DC-CIK followed by metronomic cyclophosphamide therapy as salvage treatment for triple negative metastatic breast cancers patients (aged <45).前瞻性研究环磷酰胺、噻替哌、卡铂联合过继性树突状细胞-细胞因子诱导的杀伤细胞后序贯环磷酰胺节拍疗法治疗三阴性转移性乳腺癌患者（<45 岁）。
Clin Transl Oncol. 2016 Jan;18(1):82-7. doi: 10.1007/s12094-015-1339-2. Epub 2015 Aug 13.
4
Metronomic cyclophosphamide eradicates large implanted GL261 gliomas by activating antitumor Cd8 T-cell responses and immune memory.小剂量节拍性环磷酰胺通过激活抗肿瘤CD8 T细胞反应和免疫记忆来根除大型植入性GL261胶质瘤。
Oncoimmunology. 2015 Feb 18;4(4):e1005521. doi: 10.1080/2162402X.2015.1005521. eCollection 2015 Apr.
5
Immune targeting in breast cancer.乳腺癌中的免疫靶向治疗
Oncology (Williston Park). 2015 May;29(5):375-85.
6
On and off metronomic oral vinorelbine in elderly women with advanced breast cancer.晚期乳腺癌老年女性间歇性口服长春瑞滨的研究
Tumori. 2015 Jan-Feb;101(1):30-5. doi: 10.5301/tj.5000207. Epub 2015 Feb 5.
7
Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer.帕妥珠单抗、曲妥珠单抗和多西他赛用于HER2阳性转移性乳腺癌的治疗
N Engl J Med. 2015 Feb 19;372(8):724-34. doi: 10.1056/NEJMoa1413513.
8
Paclitaxel and bevacizumab with or without capecitabine as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a multicentre, open-label, randomised phase 2 trial.紫杉醇和贝伐珠单抗联合或不联合卡培他滨作为 HER2 阴性局部复发性或转移性乳腺癌的一线治疗：一项多中心、开放标签、随机 2 期试验。
Eur J Cancer. 2014 Dec;50(18):3077-88. doi: 10.1016/j.ejca.2014.10.008.
9
Safety and efficacy of neratinib in combination with capecitabine in patients with metastatic human epidermal growth factor receptor 2-positive breast cancer.奈拉替尼联合卡培他滨治疗转移性人表皮生长因子受体 2 阳性乳腺癌患者的安全性和有效性。
J Clin Oncol. 2014 Nov 10;32(32):3626-33. doi: 10.1200/JCO.2014.56.3809. Epub 2014 Oct 6.
10
Chemotherapy and targeted therapy for women with human epidermal growth factor receptor 2-negative (or unknown) advanced breast cancer: American Society of Clinical Oncology Clinical Practice Guideline.人表皮生长因子受体2阴性（或未知）晚期乳腺癌女性的化疗与靶向治疗：美国临床肿瘤学会临床实践指南
J Clin Oncol. 2014 Oct 10;32(29):3307-29. doi: 10.1200/JCO.2014.56.7479. Epub 2014 Sep 2.
Zotero 插件